Receptor Occupancy Fails to Predict Immune Activation in Pembrolizumab Dosing Study
A translational modelling study finds that PD-1 receptor occupancy does not predict immune activation during pembrolizumab therapy, challenging current dosing ...
Tag: pembrolizumab
Dual Immunotherapy Edges Out Pembrolizumab in Cost-Effectiveness for MSI-High Colorectal Cancer
A new cost-effectiveness analysis finds nivolumab plus ipilimumab may offer greater quality-adjusted life years at lower cost than pembrolizumab as ...
Immune Side Effects May Signal Stronger Tumor Shrinkage and Longer Survival in Gastric Cancer
A Japanese study found that immune-related adverse events during checkpoint inhibitor therapy for advanced gastric cancer were independently linked to ...
Five-Year Data Confirm Lasting Benefit of Pembrolizumab Chemotherapy Combo in Cervical Cancer
Five-year results from the KEYNOTE-826 trial confirm that adding pembrolizumab to first-line chemotherapy delivers durable survival benefit for patients with ...
Triple-Drug Antibody-Drug Conjugate Strategy Shows Promise in Hard-to-Treat Breast Cancer
A real-world study of 87 patients suggests that combining Trop-2 antibody-drug conjugates with PD-1 inhibitors and anti-angiogenic therapy substantially improves ...
-
Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study
-
University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept
-
Bee body mass, pathogens and local climate influence heat tolerance
-
Researchers record first-ever images and data of a shark experiencing a boat strike
-
Groundbreaking Clinical Trial Reveals Lubiprostone Enhances Kidney Function
Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!